New publication – Attana’s technology employed to validate isolation of cholesterol carriers for application for patients having cardiovascular diseases

18 September 2019 - 09:40

A new paper has been published in Scientific Reports by Prof. Riekkola and co-workers at the University of Helsinki and the group of Prof. Fornstedt at Karlstad University. In this paper, a new method to isolate cholesterol carrying particles from human plasma was developed. Attana's QCM technology was employed to evaluate the efficacy of the method.

Low-density lipoproteins (LDL) is a main cholesterol carrier in the body and is considered the major risk factor for the development of atherosclerotic cardiovascular diseases. Rapid isolation of these LDL particles from human plasma is needed for studies of their function.

In this paper, a novel and rapid method for the isolation of LDL particles from human plasma was developed using affinity chromatography. The isolation method consists of two affinity disk columns, immobilized with two different capturing agents to increase the selectivity. The first disk removes unwanted particles from the sample and the second disk captures the LDL particles.

Attana´s QCM technology was used to evaluate and validate the developed method. LDL particles were isolated from plasma from two healthy individuals both with the new method and a conventional method (ultracentrifugation). An antibody was immobilized on the Attana chip and the kinetic interaction profiles of the isolated LDL particles were analyzed with Attana’s technology. Additionally, the rate constant distributions were determined using an algorithm and plotted as clusters. In total, five different interactions were identified. This provides a possibility for a deeper understanding of the interactions compared to the information obtained from conventional methods for data fitting.

This is a continuation of the previous work performed at the group of Prof Riekkola and in addition, a first application for the new data analysis algorithms developed by Prof Fornstedt and co-workers and Attana.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More